RecruitingNCT06682325

Pharmaco-proteomic Platform to Evaluate Drug Interactions in Liver Transplant Patients

Development of a Pharmaco-proteomic Platform to Evaluate Potential Drug Interactions and Their Clinical Impact in Liver Transplant Patients Undergoing Multidrug Treatment


Sponsor

Pontificia Universidad Catolica de Chile

Enrollment

48 participants

Start Date

Jun 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to enhance the ability to forecast kidney failure in liver transplant patients in the ICU under multidrug treatment by developing a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data. The main outcomes it aims to develop are: 1. Design the multidrug web computing platform with available information on drug pair interactions (DDIs). 2. Integrate the proteomic and clinical data of liver transplant patients into the IT platform. 3. Implement the multidrug web platform to predict the clinical evolution of liver transplant patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Liver transplant patients undergoing surgery at UC Christus Hospital

Exclusion Criteria2

  • Patients on renal replacement therapy
  • Patients for whom no clinical or pharmacological registry is available

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMulti-drug interaction

The clinical impact associated with the use of multiple drugs in liver transplant patients during their stay in ICU will be evaluated.


Locations(3)

Hospital ClínicoUC-Christus

Santiago, Santiago Metropolitan, Chile

Pontificia Universidad Católica de Chile

Santiago, Santiago Metropolitan, Chile

Universidad de Valparaíso

Valparaíso, Valparaiso, Chile

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06682325


Related Trials